Why the breakthrough pancreatic cancer drug stops working: 5 notes
Most patients with advanced pancreatic cancer treated with daraxonrasib will see the drug lose its effect, and researchers are starting to identify why, according to a Sept. 30 report in The New York Times. The FDA approved Revolution Medicines’ daraxonrasib Aug. 26 after trial data showed pancreatic cancer patients who received the drug lived almost […] The post Why the breakthrough pancreatic cancer drug stops working: 5 notes appeared first on Becker's Hospital Review | Healt...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.